Quick Answer
Entera Bio Ltd. reported Total Revenue of $42.0 thousand for fiscal year 2025.
Entera Bio Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $42.0K -76.8% |
$181.0K | $0.00 -100.0% |
$134.0K -76.5% |
$571.0K +56.4% |
$365.0K |
| Net Income | -$11.44M -19.9% |
-$9.54M -7.3% |
-$8.89M +32.0% |
-$13.07M -7.3% |
-$12.19M -8.7% |
-$11.22M |
| Diluted EPS | $0.25 +0.0% |
$0.25 -19.4% |
$0.31 -31.1% |
$0.45 -4.3% |
$0.47 | — |
| Total Assets | $15.99M +70.3% |
$9.39M -20.2% |
$11.77M -10.4% |
$13.13M -49.5% |
$25.99M +167.3% |
$9.72M -41.8% |
| Cash and Equivalents | $7.11M -17.9% |
$8.66M -21.4% |
$11.02M -10.5% |
$12.31M -50.6% |
$24.89M +189.7% |
$8.59M |
| Stockholders Equity | $13.10M +62.1% |
$8.08M -22.2% |
$10.39M -11.6% |
$11.75M -47.9% |
$22.57M +200.5% |
$7.51M -45.5% |
| R&D Expense | $6.00M +33.5% |
$4.50M -0.2% |
$4.51M -22.9% |
$5.85M -13.6% |
$6.77M +6.1% |
$6.38M -11.3% |
| Operating Income | -$11.53M -20.3% |
-$9.59M -7.8% |
-$8.89M +31.7% |
-$13.02M -6.5% |
-$12.22M -9.4% |
-$11.17M |
| Gross Profit | $0.00 -100.0% |
$9.0K | $0.00 -100.0% |
$33.0K -83.3% |
$198.0K +204.6% |
$65.0K |
| Shares Outstanding | 46.18M +18.9% |
38.84M +9.5% |
35.48M +23.1% |
28.81M +0.0% |
28.80M +36.8% |
21.06M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$3.20M | -5.9% | -20.5% |
| Diluted EPS | September 30, 2025 | $0.07 | -12.5% | +16.7% |
| Total Assets | September 30, 2025 | $17.41M | +124.9% | -11.5% |
| Cash and Equivalents | September 30, 2025 | $8.57M | +24.0% | -21.0% |
| Stockholders Equity | September 30, 2025 | $15.23M | +136.1% | -11.7% |
| R&D Expense | September 30, 2025 | $1.64M | +11.2% | +8.1% |
| Operating Income | September 30, 2025 | -$3.26M | -7.8% | -22.0% |
| Gross Profit | September 30, 2025 | $0.00 | — | — |
| Shares Outstanding | September 30, 2025 | 45.66M | +25.1% | +0.5% |
- Entera Bio Ltd. reported Total Revenue of $42.0 thousand for fiscal year 2025.
- Entera Bio Ltd. showed a decrease of -76.8% in Total Revenue compared to the prior fiscal year.
- Entera Bio Ltd. reported Net Income of -$11.44 million for fiscal year 2025.
- Entera Bio Ltd. showed a decrease of -19.9% in Net Income compared to the prior fiscal year.
- Entera Bio Ltd. reported Diluted EPS of $0.25 per share for fiscal year 2025.
- Entera Bio Ltd. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- Entera Bio Ltd. reported Total Assets of $15.99 million for fiscal year 2025.
- Entera Bio Ltd. showed an increase of +70.3% in Total Assets compared to the prior fiscal year.
- Entera Bio Ltd. reported Cash and Equivalents of $7.11 million for fiscal year 2025.
- Entera Bio Ltd. showed a decrease of -17.9% in Cash and Equivalents compared to the prior fiscal year.
- Entera Bio Ltd. reported Stockholders Equity of $13.10 million for fiscal year 2025.
- Entera Bio Ltd. showed an increase of +62.1% in Stockholders Equity compared to the prior fiscal year.
- Entera Bio Ltd. reported R&D Expense of $6.00 million for fiscal year 2025.
- Entera Bio Ltd. showed an increase of +33.5% in R&D Expense compared to the prior fiscal year.
- Entera Bio Ltd. reported Operating Income of -$11.53 million for fiscal year 2025.
- Entera Bio Ltd. showed a decrease of -20.3% in Operating Income compared to the prior fiscal year.
- Entera Bio Ltd. reported Gross Profit of $0.00 for fiscal year 2025.
- Entera Bio Ltd. showed a decrease of -100.0% in Gross Profit compared to the prior fiscal year.
- Entera Bio Ltd. reported Shares Outstanding of 46.18 million shares for fiscal year 2025.
- Entera Bio Ltd. showed an increase of +18.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: